The stock of Intellia Therapeutics Inc. (NASDAQ:NTLA) decreased by -$0.04 on Friday to finish at $39.51, down -0.10 percent. The last five days have seen an average of 778,680 shares of common stock traded. 12 times new highs were reached in the current year, with a gain of $4.62. The average number of shares traded over the last 20 days was 777,675, while the average volume over the last 50 days totaled 913,982.
NTLA stock dropped -13.70% since last month. On 08/03/23, the company’s shares reached a one-month low of $38.05. The stock touched a high of $69.73 on 06/14/23, after rallying from a low of $32.44 in 52 weeks. The price of NTLA stock has risen by 13.24% or $4.62 this year, reaching a new high 12 times. Still, the stock price is down -43.34% from the 52-week high.
Insider Transactions
NTLA stock investors should be aware that Intellia Therapeutics Inc. (NTLA) stock had its last reported insider trading activity 14 days ago on Jul 31. On Jul 31, Director Bhanji Muna sold 265 shares at $42.33 each. This transaction resulted in the insider making $11,217. On Jul 06, Bhanji Muna sold 1,867 shares at a price of US$39.30. After the transaction, the insider now owns 12,526 shares. EVP, Chief Technical Officer Clark Eliana had earlier sold 360 shares on Jul 03 for $40.51 a share. The transaction was completed for $14,584.
Valuation Metrics
Beta for the stock is 1.83. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 66.03, the price-to-book (PB) ratio of 3.15.
Financial Health
For the three months ended June 29, Intellia Therapeutics Inc.’s quick ratio was 9.40, while its current ratio was 9.40, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $510.29 million and revenue of $52.12 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. NTLA’s return on assets (ROA) during the last 12 months has been -33.90%. There was a -37.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -41.60%.
Earnings Surprise
According to Intellia Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $736.27 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $13.59 million, while revenues fell by -3.24% to $12.61 million. It was predicted that Intellia Therapeutics Inc.’s quarterly earnings would be -$1.4, but it ended up being -$1.32, beating the consensus by -6.10%. EBITDA was -$130.16 million for the quarter. At the end of Intellia Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 218.35 million, while its total debt was $122.33 million. Equity owned by shareholders amounts to $88.49 million.
Technical Picture
Here’s a quick look at Intellia Therapeutics Inc.’s (NTLA) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 39.07%, suggesting the stock is Neutral, with a 27.95% historical volatility rate.
The stochastic %K and %D were 29.66% and 27.45% respectively, while the average true range (ATR) was 1.62. Based on the 14-day stochastic reading of 29.14%, the RSI (14) reading is 41.78%. On the 9-day MACD Oscillator, the stock is at -0.03, and the 14-day reading is at -0.77.
Analyst Ratings
In its analyst report released on April 13, 2023, Canaccord Genuity began covering Intellia Therapeutics Inc. (NASDAQ: NTLA). The stock was rated as a Buy by the brokerage firm. Analysts have assigned Intellia Therapeutics Inc. (NTLA) an Buy rating. NTLA is a stock that is recommended for selling by 0 brokerage firms, while 4 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 3 rates it overweight and 22 others recommend it as a buy.
What is NTLA’s price target for the next 12 months?
The current consensus forecast for the stock is between $38.00 and $157.00, with a median target price of $80.00. In analyzing these forecasts, the average price target given by analysts for Intellia Therapeutics Inc. (NTLA) is $83.56.
